909
289
7
9
280
Cat. No. | Product Name | ||
---|---|---|---|
L5900 | 血脑屏障通透化合物库 | 509 compounds | |
509 个 CNS-Penetrant 生物活性小分子化合物的特有集合,用于高通量、高内涵筛选; | |||
L7110 | 抗高血压化合物库 | 678 compounds | |
678 种高血压相关的小分子,用于高通量和高内涵筛选; | |||
L4020 | NO PAINS 化合物库 | 9384 compounds | |
TargetMol NO PAINS 化合物库包含 9384 个剔除了PAINS 的小分子活性化合物,可用于新药研发,信号通路研究,老药新用等研究。 | |||
L1380 | 转录因子库 | 695 compounds | |
695 种转录因子靶向、结构新颖的化合物; | |||
L2610 | 神经递质受体化合物库 | 1513 compounds | |
1513 种与神经递质受体相关的化合物,用于高通量、高内涵筛选; | |||
L4710 | 非甾体类抗炎化合物库 | 521 compounds | |
521 种非甾体类的抗炎相关化合物,可用于高通量和高内涵筛选; | |||
L9830 | 抗帕金森病化合物库 | 857 compounds | |
857 种帕金森病相关的化合物集合,可用于高通量和高内涵筛选; |
Cat. No. | Product Name | Form | Specificity Of Inhibition |
---|---|---|---|
CL0061 |
Histone Methyltransferase inhibitor kit
Histone Methyltransferase inhibitor kit |
||
C0084 |
Magrose Beads NH2 (10-30 μm, Ultra-suspension)
琼脂糖氨基磁珠 (10-30 μm) |
||
C0111 |
Magrose Beads NTA-Nickel (Ultra-suspension)
His-tag 蛋白纯化磁珠 NTA-Ni |
||
CL0088 |
Angiotensin Receptor inhibitor kit
Angiotensin Receptor inhibitor kit |
||
C0086 |
Magrose Beads COOH (10-30 μm, Ultra-suspension)
琼脂糖羧基磁珠 (10-30 μm) |
||
CL0150 |
DNA Methyltransferase/Demethylase inhibitor kit
DNA Methyltransferase/Demethylase inhibitor kit |
||
CL0077 |
Reverse Transcriptase inhibitor kit
Reverse Transcriptase inhibitor kit |
||
C0079 |
Magrose Beads OH (10-30 μm, Ultra-suspension)
琼脂糖羟基磁珠 (10-30 μm) |
||
C0095 |
Magrose Beads Streptavidin (Ultra-suspension)
琼脂糖链霉亲和素磁珠 |
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T3543 |
NS-638
NS 638 |
Calcium Channel | Membrane transporter/Ion channel; Metabolism |
NS-638 是一种 Ca2+ 通道阻滞剂,可阻断 K+ 刺激的细胞内 Ca2+ 升高,IC50值为3.4 μM。 | |||
T28197 |
NS-2710
NS2710,NS 2710 |
||
NS-2710, a GABA receptor agonist, is used potentially for the treatment of anxiety. | |||
T8494 |
NS-3-008 hydrochloride
NS-3-008 HCl |
Others | Others |
NS-3-008 hydrochloride (NS-3-008 HCl) 是一种口服具有活性的G0s2转录抑制剂(IC50:2.25 μM)。它可用于慢性肾脏疾病的研究。 | |||
T16344 |
NS-2028
|
Others; Guanylate cyclase | GPCR/G Protein; Others |
NS-2028 是一种高度选择性的可溶性鸟苷酸环化酶抑制剂。它抑制 3-吗啉代-sydnonimine 在人培养的脐静脉内皮细胞中形成环状 GMP,IC50为30mM。它抑制小鼠小脑匀浆和神经元 NO 合酶中的可溶性鸟苷酸环化酶活性,IC50分别为 17 和 20 mM。它可降低血管内皮生长因子诱导的血管生成和通透性。 | |||
T4294 |
NS 11021
NS11021 |
Potassium Channel | Membrane transporter/Ion channel |
NS 11021 (NS11021) 是特异性 Ca2+激活的大电导 K+(KCa1.1)通道激活剂。当浓度高于0.3 μM 时,它通过平行移动通道激活曲线产生更多负电位,以浓度依赖的方式激活 KCa1.1。 | |||
T3102 |
NS-1619
|
Apoptosis; Potassium Channel | Apoptosis; Membrane transporter/Ion channel |
NS 1619 是 Ca2+激活的 K+(BK) 通道的激活剂,是一种高效的松弛剂,在血管和其他组织的几个平滑肌中的 EC50约为 10 – 30 μM。它抑制A2780卵巢癌细胞增殖并诱导细胞凋亡。 | |||
T7884 |
NS 1738
NSC 213859 |
AChR | Neuroscience |
NS 1738 (NSC-213859) 是含有 α7 的神经元烟碱乙酰胆碱受体 (nAChRs) 的正变构调节剂。在卵母细胞实验中,正调节 α7nAChR,EC50为 3.4 μM。 | |||
T3214 |
NS-398
N-(2-cyclohexyloxy-4-nitrophenyl)methane sulfonamide,NS398 |
COX | Immunology/Inflammation; Neuroscience |
NS-398 (N-(2-cyclohexyloxy-4-nitrophenyl)methane sulfonamide) 是一种非甾体类抗炎剂,具有解热作用,可用于缓解疼痛的研究。它选择性抑制 COX-2的活性,IC50值为 3.8 μM。 | |||
T2067 |
NS11394
NS 11394 |
GABA Receptor | Membrane transporter/Ion channel; Neuroscience |
NS11394 是可口服GABAA 的阳性变构调节剂 (PAM),Ki 值为 0.5 nM。它对GABAA 的选择性依次为 α5、α3、α2 和α1 受体,具有抗炎和抗焦虑活性。 | |||
T28199 |
NS9283
NS 9283,NS-9283 |
AChR | Neuroscience |
NS9283 是有效的(α4)3(β2)2烟碱型ACh 受体的正向变构调节剂。NS9283在一系列神经系统疾病中有研究价值,如注意力缺陷多动障碍、精神分裂症、帕金森病和阿尔茨海默病。 | |||
T16348 |
NS5806
NS-5806 |
Potassium Channel | Membrane transporter/Ion channel |
NS5806 是钾电流的激活剂,可增加 KV4.3/KChIP2峰值电流幅度,EC50值为 5.3 μM。它会在包含 KChIP2 的通道复合体中降低 KV4.2 和 KV4.3 电流衰减。 | |||
T16346 |
NS1652
|
Chloride channel | Membrane transporter/Ion channel |
NS1652 是可逆阴离子电导抑制剂,在人和小鼠的红细胞中,可以抑制氯离子通道,IC50值为 1.6 μM。 | |||
T3192 |
NS1643
|
Potassium Channel; HER; Autophagy | Angiogenesis; Autophagy; JAK/STAT signaling; Membrane transporter/Ion channel; Tyrosine Kinase/Adaptors |
NS1643 是一种有效的人类 ether-a-go-go 相关基因 (hERG) KV11.1 通道激活剂,EC50 为 10.5 μM。它增加了复极保留,展示出新型抗心律失常的方法。它通过减少通道失活,在高浓度下,对 erg2 (Kv11.2) 电流有明显影响。 | |||
T12266L2 |
Ilginatinib hydrochloride
NS-018 hydrochloride |
Tyrosine Kinases; JAK | Angiogenesis; Chromatin/Epigenetic; JAK/STAT signaling; Stem Cells; Tyrosine Kinase/Adaptors |
Ilginatinib hydrochloride (NS-018 hydrochloride) 是一种可口服的 JAK2强效抑制剂,IC50值为 0.72 nM,对其选择性是对 JAK1、JAK3和 Tyk2 的 46、54 和 22 倍,IC50分别为 33、39 和 22 nM。 | |||
T12255 |
NS19504
|
Potassium Channel | Membrane transporter/Ion channel |
NS19504 是 Ca2+激活的 K+通道激活剂 (EC50=11.0 µM),对膀胱平滑肌自发性相位收缩具有松弛作用。 | |||
T28196 |
NS-220
LS-191458,NS 220 |
||
NS-220, a selective agonist of peroxisome proliferator-activated receptor alpha, potently decreases plasma triglyceride and glucose levels and modifies lipoprotein profiles in KK-Ay mice. | |||
T33734 |
NS 11
NS-11,NS11 |
||
NS 11 is an RGD-nonpeptidic mimetic. | |||
T9542 |
NS3861
|
AChR | Neuroscience |
NS3861 是烟碱型乙酰胆碱受体的激动剂,对α3β4 nAChR 具有高亲和力。能够分别与α3β4 (Ki:0.62 nM)、α3β2 (Ki:25 nM)、α4β4 (Ki:7.8 nM)、α4β2 (Ki:55 nM) 结合。 | |||
T4612 |
NS309
|
EGFR; Potassium Channel; HER | Angiogenesis; JAK/STAT signaling; Membrane transporter/Ion channel; Tyrosine Kinase/Adaptors |
NS309 是选择性钙依赖性钾离子通道 SK/IK 的激活剂,在 BK 通道上没有激活作用。 | |||
T22119 |
NS3694
|
Apoptosis | Apoptosis |
NS3694 是一种凋亡抑制剂,可抑制凋亡小体形成和半胱天冬酶活化。 | |||
T69550 | NS-3736 | ||
NS-3736 is a chloride channel inhibitor that has been shown to prevent osteoclastic acidification and resorption. | |||
T16347 |
NS3623
|
Potassium Channel | Membrane transporter/Ion channel |
NS3623 是 hERG1 (KV11.1)钾通道激活剂,激活IKr 和Ito 电流,具有抗心律失常作用。NS3623也是 hERG1 通道抑制剂。 | |||
T12266L |
Ilginatinib maleate
NS-018 maleate |
Tyrosine Kinases; JAK | Angiogenesis; Chromatin/Epigenetic; JAK/STAT signaling; Stem Cells; Tyrosine Kinase/Adaptors |
Ilginatinib maleate (NS-018 maleate) 是一种可口服的 JAK2强效抑制剂,IC50值为 0.72 nM,对其选择性是对 JAK1、JAK3和 Tyk2 的 46、54 和 22 倍,IC50分别为 33、39 和 22 nM。 | |||
T12266 |
Ilginatinib
NS-018 |
Tyrosine Kinases; JAK | Angiogenesis; Chromatin/Epigenetic; JAK/STAT signaling; Stem Cells; Tyrosine Kinase/Adaptors |
Ilginatinib (NS-018) 是一种可口服的JAK2强效抑制剂,IC50值为 0.72 nM,对其选择性是对 JAK1、JAK3和 Tyk2 的 46、54 和 22 倍,IC50分别为 33、39 和 22 nM。 | |||
T1752 |
NS6180
|
Potassium Channel | Membrane transporter/Ion channel |
NS6180是一种高效的KCa3.1离子通道选择性抑制剂,IC50值9nM。NS6180阻止T 细胞活化和炎症反应。 | |||
T12256 |
NS8593 hydrochloride
NS8593 HCl |
Potassium Channel | Membrane transporter/Ion channel |
NS8593 hydrochloride (NS8593 HCl) 是选择性的 SK 通道抑制剂。它可逆抑制 SK3介导的电流,Kd 值为 77 nM。它抑制所有 SK1-3亚型的 Ca2+依赖性 (在 0.5 μM Ca2+时,Kd 分别为 0.42、0.60 和 0.73 μM),并且不影响中间电导和大电导的钙激活钾通道。 | |||
T26364 |
NS-2359 citrate
GSK-372475,GSK 372475 citrate,NS2359,GSK 372475,NS 2359,GSK372475,NS-2359 |
||
NS-2359 is a serotonin-norepinephrine-dopamine reuptake inhibitor. | |||
T37390 |
NS 6740
|
||
High affinity α7 nAChR partial agonist (Ki = 1.1 nM in rat; Emax < 10% of the response to ACh in rat and human). Inhibits ACh (IC50 = 2.7 nM) at α7 nAChR. Reduces LPS-induced TNF-α release from microglia enriched cultures. Anti-inflammatory. Briggs et al (2009) Role of channel activation in cognitive enhancement mediated by α7 nicotinic acetylcholine receptors. Br.J.Pharmacol. 158 1486 PMID:19845675 |Thomsen et al (2012) The α7 nicotinic acetylcholine receptor ligands methyllycaconitine, NS674... | |||
T37389 |
NS 383
|
||
ASIC blocker (IC50 values are 0.44, 2.1 μM and no effect at rat ASIC1a, ASIC3 and ASIC2a, respectively: IC50 value = 0.12 μM at human ASIC1a with no effect at ASIC2a or ASIC3). Inhibition was also observed at heteromeric ASIC channels (IC50 values are 0.79, 0.87 and 4.5 uM at rat ASIC1a+3, ASIC1a+2a and ASIC2a+3; IC5O values are 0.33 and 0.69 uM at human ASIC1a+2a and ASIC1a+3, with no effect at ASIC2a+3). Attenuates pathophysiological nociceptive behaviors in CFA-inflamed and CCI rats. | |||
T38779 |
NS-102
|
||
NS-102 is a powerful and selective antagonist of the kainate receptor (GluK2), as well as a potent antagonist of the GluR6/7 receptor. | |||
T16732 |
Reproxalap
NS-2,ADX-102 |
Others | Others |
Reproxalap (NS-2) 是一种活性醛类隔离剂,可用于干眼症的研究。它能够与醛 (包括丙二醛和 4-羟基壬醛) 共价结合。 | |||
T29687 |
Afacifenacin
Afacifenacin fumarate,SMP-986,NS 986,NS-986,SMP 986,NS986,SMP986 |
AChR | Neuroscience |
Afacifenacin (SMP-986) fumarate 是一种 M3 毒蕈碱受体选择性拮抗剂,可用于研究缺血性心脏病,尿失禁和膀胱炎和其他疾病。 | |||
T23088 |
NS 3763
|
Others | Others |
NS 3763 is a kainate receptor antagonist. | |||
T4009 |
NS 1209
SPD 502 |
GluR | Neuroscience |
NS 1209 (SPD 502) 是一种 AMPA 受体拮抗剂。 | |||
T3216 |
Selexipag
NS-304,ACT-293987,赛乐西帕,Uptravi |
Others; Prostaglandin Receptor | GPCR/G Protein; Immunology/Inflammation; Others |
Selexipag (ACT-293987) 是前列环素受体激动剂,可引起肺血管舒张,用于治疗肺动脉高压。 | |||
T16345 |
NS13001
N-(4-chlorophenyl)-2-(3,5-dimethylpyrazol-1-yl)-9-methylpurin-6-amine,N-(4-Chlorophenyl)-2-(3,5-dimethyl-1H-pyrazol-1-yl)-9-methyl-9H-purin-6-amine |
Potassium Channel | Membrane transporter/Ion channel |
NS13001 (N-(4-Chlorophenyl)-2-(3,5-dimethyl-1H-pyrazol-1-yl)-9-methyl-9H-purin-6-amine) 是口服有效的 SK 通道选择性正向变构调节剂。NS13001 对 SK2 和 SK3 通道的 EC50分别为 1.8 μM 和 0.14 μM。NS13001 在脊髓小脑共济失调 2 型和其他小脑共济失调方面具有研究价值。 | |||
T6311 |
Bafetinib
NS-187,巴氟替尼,INNO-406 |
Bcr-Abl; Src; Autophagy | Angiogenesis; Autophagy; Cytoskeletal Signaling; Tyrosine Kinase/Adaptors |
Bafetinib (INNO-406) 是一种特异性双重 Bcr-Abl/Lyn 抑制剂,IC50值为5.8和19 nM。 | |||
T33735 | NS-1231 | ||
NS-1231 exhibits neurotrophic-like effects in vitro and in vivo. | |||
T69747 |
NS-3956 free base
|
||
NS-3956 free base is a partial nAChR α4β2 LS and HS agonist with analgesic properties. | |||
T5520L |
Cetrorelix diacetate
NS-75A,醋酸西曲瑞克,SB-075 acetate,SB-075 diacetate,Cetrorelix acetate,NS-75A diacetate |
GNRH Receptor | GPCR/G Protein |
Cetrorelix diacetate (NS-75A) 是GnRH 受体的强效拮抗剂(IC50:1.21 nM)。 | |||
T69746 |
NS-3956 fumaric acid salt
|
||
NS-3956 fumaric acid salt is a partial nAChR α4β2 LS and HS agonist with analgesic properties. | |||
T6481 |
Droxinostat
NS 41080,4-(4-氯-2-甲基苯氧基)-N-羟基丁酰胺 |
Apoptosis; HDAC | Apoptosis; Chromatin/Epigenetic; DNA Damage/DNA Repair |
Droxinostat (NS 41080) 是HDAC3、HDAC6和HDAC8抑制剂,IC50分别为16.9、2.47和1.46 μM。 | |||
T71486 |
NS-0011
|
||
NS-0011 is an inhibitor of CDK5 translocation which increases CDK5 accumulation in the nucleus, suppressing both cancer cell proliferation and xenograft tumorigenesis. | |||
T73572 |
NS-8
|
||
NS-8,一种吡咯衍生物,能够激活Ca2+-敏感的K+通道。通过降低盆腔传入神经活动,NS-8有助于抑制排尿反射,适用于尿频与尿失禁的研究。 | |||
T28198 |
NS5818
NS-5818,NS 5818 |
||
NS5818 inhibits ClC. | |||
T28195 |
NS004
NS 004,NS-004 |
||
NS004 is a large-conductance K+ channel opener, it inhibits mitochondrial function in glioma cells. | |||
T24547 |
NS4591
NS 4591,NS-4591 |
||
NS4591 is a modulator of SK-IK channels. | |||
T28951 |
Tesofensine
NS 2330,NS2330,NS-2330 |
||
Tesofensine, a serotonin–noradrenaline–dopamine reuptake inhibitor, is used potentially for the treatment of obesity. | |||
T15233 |
Endovion
NS3728 |
Chloride channel | Membrane transporter/Ion channel |
Endovion (NS3728) 是阴离子通道抑制剂 和 Anoctamin-1 (ANO 1) 通道抑制剂,也是特异性的 VRAC/VSOAC 阻断剂。 | |||
T26361 |
Brasofensine sulfate
NS 2214,BMS 204756,NS2214,NS-2214,BMS-204756 |
||
Brasofensine sulfate is a dopamine reuptake inhibitor. |
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T13626 | Cottonseed oil | Others | Others |
Cottonseed oil 是一种提取自棉花种子中的食用油,是一种植物油中杀虫能力极强的油。 | |||
TN2282 |
trans-Stilbene
反式-1,2二苯乙烯,1,2-Diphenylethylene (trans),(E)-Stilbene |
Others | Others |
trans-Stilbene (1,2-Diphenylethylene (trans)) 可用于制备荧光增白剂、染料激光器、非甾体合成雌激素。 | |||
T5256 |
All-trans-retinal
视黄醛,All trans-Retinal,Retinaldehyde,Vitamin A aldehyde |
Others; Endogenous Metabolite | Metabolism; Others |
All-trans-retinal (Vitamin A aldehyde) 是视网膜中维生素A 代谢物之一。 生理条件下,它再生为视觉发色团,11-顺式-视黄醛。 | |||
TCS1554 |
trans-Benzylideneacetone
反式苯亚甲基丙酮,Acetocinnamone,亚苄基丙酮 |
Phospholipase | Metabolism |
trans-Benzylideneacetone (Acetocinnamone) 是一种革兰氏阴性致病性线虫细菌嗜线虫(Xenorhabdus nematophila) 的代谢产物,是一种针对磷脂酶 A2 (PLA2) 的酶抑制剂,也是一种免疫抑制剂。 | |||
TN6930 |
5-Desmethylsinensetin
|
Others | Others |
5-desmethylsinensetin 是分离自Stevia satureiifoliavar.satureiifolia 的天然产物,显示出抗原生动物的活性,抑制T. cruzi epimastigotes 和trypomastigotes 的IC50分别为 0.4 μg/mL 和75.1 μg/mL。 | |||
T3812 |
(20R)-Ginsenoside Rg3
人参皂甙 RG3,(20R)-人参皂苷Rg3,20(R)-Ginsenoside Rg3,(20R)Ginsenoside Rg3,20(R)-Propanaxadiol |
Others | Others |
(20R)-Ginsenoside Rg3 (20(R)-Propanaxadiol) 是一种人参根中的化合物,具有抑制血管内皮细胞增生(IC50= 10 nM)和抗肿瘤作用。 | |||
T36473 |
trans-Nerolidol
|
||
trans-Nerolidol is a sesquiterpene that has been found in various plants, includingC. sativa, and has diverse biological activities, including antimicrobial, antioxidant, anticancer, and insecticidal properties.1,2,3,4In a disc assay,trans-nerolidol inhibits the growth ofS. aureus,B. subtilis,E. coli, andS. cerevisiaewith zones of inhibition measuring 10, 9, 10, and 4 mm, respectively.2It reduces viability of CaCo-2 adenocarcinoma cells with an IC50value of 28.7 mg/L and reduces production of re... | |||
T22262 |
Ansamitocin p-3
Maytansinol isobutyrate,Antibiotic C 15003P3,NSC292222 |
Microtubule Associated | Cytoskeletal Signaling |
Ansamitocin p-3 (Maytansinol isobutyrate) 是一种微管抑制剂,对微管蛋白聚合的 IC50 为 3.4 μM。 | |||
TN1117 |
Veraguensin
|
p38 MAPK; NF-κB; Antibiotic; Parasite; Antifection | MAPK; Microbiology/Virology; NF-κB |
Veraguensin 来源于 Magnolia sp.。 Veraguensin 抑制骨吸收并显示出高抗寄生虫活性。 | |||
T7408 |
all-trans-4-Oxoretinoic acid
4-KETO全反式维甲酸,all-trans 4-Keto Retinoic Acid |
Endogenous Metabolite | Metabolism |
all-trans-4-Oxoretinoic acid (all-trans 4-Keto Retinoic Acid) 是一种维生素A 的特性代谢物,能够通过作用核维甲酸受体(RARs) 来诱导基因转录。 | |||
T3920 |
Pseudoginsenoside F11
Ginsenoside A1,拟人参皂苷 F11,拟人参皂苷F11 |
Others; Endogenous Metabolite | Metabolism; Others |
Pseudoginsenoside F11 (Ginsenoside A1) 从人参根和叶中分离得到。PF11在一系列心血管和中枢神经系统疾病中具有广泛的保护作用。 | |||
TN2100 |
Pratensein
红车轴草素,三叶草 |
Others; NF-κB | NF-κB; Others |
Pratensein 是黄酮类化合物,能够减少氧化损伤和恢复突触和 BDNF 水平,改善 β-淀粉样蛋白诱导的大鼠认知障碍。 | |||
T6S1587 |
Notoginsenoside R2
三七皂苷R2,20(S)-Notoginsenoside R2,Ginsenoside Ng-R2 |
Others; Nrf2 | Immunology/Inflammation; Others |
Notoginsenoside R2 (20(S)-Notoginsenoside R2) 是一种新分离三七皂苷,表现出对6-OHDA 诱导的氧化应激及细胞凋亡的保护作用。 | |||
TN4618 |
N-trans-Sinapoyltyramine
|
Others | Others |
N-trans-Sinapoyltyramine 对 HeLa 人癌细胞系表现出强烈的选择性细胞毒性,IC50 值为 9.77 ± 1.25 μm。 | |||
T3S1589 |
Notoginsenoside Fa
|
Others | Others |
Notoginsenoside Fa 是一种原人参二醇型皂苷,从P. notoginseng 提取出来得到,有激活和恢复退化脑功能的潜能。 | |||
TN6733 |
Kansuiphorin C
KPC,甘遂大戟萜酯C |
Others | Others |
Kansuiphorin C (KPC) 是一种具有多种生物活性的天然产物。它能够调节肠道菌群及相关代谢功能,并可以改善恶性腹水。 | |||
T38141 |
Glycerophospholipids, cephalins
Phosphatidylethanolamines (egg) |
||
Glycerophospholipids, cephalins (Phosphatidylethanolamines (egg)) 是一种从鸡蛋中分离出来的磷脂酰乙醇胺的混合物,在 sn-1和 sn-2位置有各种脂肪酰基。Glycerophospholipids, cephalins 完全水解可得到1mol 的甘油、磷酸、乙醇胺和2mol 的脂肪酸。Phosphatidylethanolamines 在膜融合和细胞分裂过程中收缩环的拆卸中起作用,可调节膜的弯曲度。Phosphatidylethanolamines 能够在没有任何蛋白质或核酸的帮助下传播传染性朊病毒。Phosphatidylethanolamines 在细菌膜中的主要作用之一是分散由阴离子膜磷脂引起的负电荷。 | |||
T6S1495 |
Ginsenoside Rk3
人参皂苷Rk3,人参皂甙 Rk3 |
Others; NF-κB | NF-κB; Others |
Ginsenoside Rk3 是存在于 Panax notoginseng 的根中。它能够抑制 HepG2 细胞中 TNF-α 诱导的 NF-κB 转录活性,IC50=14.24±1.30 μM。 | |||
T8626 |
Transtorine
1,4-DIHYDRO-4-OXOQUINOLINE-2-CARBOXYLIC ACID,1,4-二氢-4-氧代喹啉-2-羧酸 |
GluR; NMDAR | Neuroscience |
Transtorine (1,4-DIHYDRO-4-OXOQUINOLINE-2-CARBOXYLIC ACID) 是一种 GluR 和 NMDA 抑制剂。 | |||
T3227 |
Danshensu
Salvianic acid A,Dan shen suan A,丹参素 |
Apoptosis; Nrf2; Autophagy | Apoptosis; Autophagy; Immunology/Inflammation |
Danshensu (Dan shen suan A) 是丹参的有效成分,能够激活 Nrf2信号通路,具有保护心血管作用。 | |||
T3915 |
Ginsenoside Ro
人参皂苷Ro,Chikusetsusaponin 5,Polysciasaponin P3,人参皂苷 Ro,Chikusetsusaponin V |
Calcium Channel; Reductase; Prostaglandin Receptor | Endocrinology/Hormones; GPCR/G Protein; Immunology/Inflammation; Membrane transporter/Ion channel; Metabolism |
Ginsenoside Ro (Chikusetsusaponin V) 能降低 TXA2产量,较弱降低 COX-1 和 TXAS 活性,具有 Ca2+拮抗剂的抗血小板作用,IC50为 155 μM。 | |||
T3S0013 |
Ethyl trans-caffeate
咖啡酸乙酯,Ethyl caffeate,Caffeic Acid Ethyl Ester |
Others | Others |
Ethyl trans-caffeate (Caffeic Acid Ethyl Ester) 具有抗炎作用。 它是一种有前途的天然化合物,未来在慢性肝病中的应用。它是一种有效的化学预防化合物,可防止因太阳紫外线照射引起的皮肤癌变。它是与人胰腺α-淀粉酶复合的代表性抑制剂的高分辨率结构。 它强烈抑制 JB6 Cl41细胞的肿瘤转化,无毒性。 PI3K、ERK1/2 和 p38 激酶活性在体外通过与 HOEC 直接结合而受到抑制。 | |||
T2961 |
Notoginsenoside R1
Sanqi glucoside R1,Sanchinoside R1,三七皂苷R1 |
Apoptosis; ERK; Beta Amyloid | Apoptosis; MAPK; Neuroscience |
Notoginsenoside R1 (Sanchinoside R1) 是一种从三七中分离出来的皂苷,具有抗氧化、抗炎、抗血管生成和抗凋亡的活性。它有神经保护和抗缺血/再灌注损伤的心脏保护作用。 | |||
T4704 |
L-Anserine nitrate
L-鹅肌肽硝酸盐,L-Anserine nitrate salt |
Others; Endogenous Metabolite | Metabolism; Others |
L-Anserine nitrate (L-Anserine nitrate salt) 是一种存在于大多数动物组织中的二肽。在模型系统中,它是一种有效的抗氧化剂和羟基自由基清除剂。该化合物抑制醛糖和酮糖还原糖诱导的非酶蛋白糖基化。 | |||
T3813 |
20(R)-Ginsenoside Rh2
20(R)-人参皂苷 RH2,(20R)Ginsenoside Rh2,Ginsenoside Rh2,20(R)-人参皂苷Rh2 |
Apoptosis; MMP; HSV | Apoptosis; Microbiology/Virology; Proteases/Proteasome |
20(R)-Ginsenoside Rh2 (Ginsenoside Rh2) 是人参皂苷 Rh2 的次要立体异构体,具有基质金属蛋白酶抑制作用。它有抗癌、抗炎和抗氧化活性。 | |||
T4S0227 |
Sinensetin
Pedalitin permethyl ether,甜橙素 |
TNF; PGE Synthase | Apoptosis; Immunology/Inflammation |
Sinensetin (Pedalitin permethyl ether) 是从水果中发现的一种甲基化黄酮,有很强的抗血管和抗炎症的能力。 | |||
T7154 |
trans-trans-Muconic acid
|
Endogenous Metabolite | Metabolism |
trans-trans-Muconic acid 是苯的尿代谢物,能够被用作人体暴露于苯的生物标志物。 | |||
T3402 |
20(S)-Ginsenoside Rg3
20(S)-人参皂苷 Rg3,人参皂苷 Rg3,20(S)-Ginsenoside-Rg3,Rg3,20S-Ginsenoside Rg3,Ginsenoside Rg3,S-Ginsenoside Rg3 |
EGFR; Beta Amyloid; Potassium Channel; NF-κB; COX; Sodium Channel; Endogenous Metabolite | Angiogenesis; Immunology/Inflammation; JAK/STAT signaling; Membrane transporter/Ion channel; Metabolism; Neuroscience; NF-κB; Tyrosine Kinase/Adaptors |
20(S)-Ginsenoside Rg3 (Rg3) 是红参的主要成分,通过抑制肿瘤细胞的粘附和侵袭来抑制肿瘤细胞肺转移。它抑制Na+和hKv1.4通道,IC50分别为 32.2±4.5 和 32.6±2.2 μM。它还抑制Aβ,NF-κB 活性和COX-2表达,抑制人脐静脉内皮细胞的增殖并具有抗血管生成活性。 | |||
T0783 |
Mianserin hydrochloride
Mianserin HCl,Org GB 94,盐酸米安色林,ORG GB-94 HCl |
Dopamine Receptor; 5-HT Receptor; Opioid Receptor; Adrenergic Receptor; Histamine Receptor | Endocrinology/Hormones; GPCR/G Protein; Immunology/Inflammation; Neuroscience |
Mianserin hydrochloride (Org GB 94) 是一种有抗抑郁活性的 H1 受体反向激动剂。 | |||
TMS2181 |
trans-Zeatin
(E)-Zeatin,玉米素 |
ERK; MEK; Endogenous Metabolite | MAPK; Metabolism |
trans-Zeatin ((E)-Zeatin) 是植物细胞分裂素,可抑制紫外线诱导的MEK/ERK 的活化,在细胞生长、分化和分裂中起着重要的作用。 | |||
T3330 |
trans-Trimethoxyresveratrol
trans-trismethoxy Resveratrol,E-Resveratrol Trimethyl Ether,MR-3,Tri-O-methylresveratrol,白藜芦醇三甲醚,3,4',5-Trimethoxy-trans-stilbene,Trimethoxystilbene |
Reactive Oxygen Species | Immunology/Inflammation; Metabolism; NF-κB |
trans-Trimethoxyresveratrol (MR-3) 是一种 Resveratrol(RSV) 的衍生物,与Resveratrol(RSV)相比,它可能是一个更有效的抗炎、抗血管新生的化合物。 | |||
TN2245 |
Sunset Yellow FCF
Food Yellow 3,Orange Yellow S,Sunset yellow,CI 15985 |
Androgen Receptor | Endocrinology/Hormones |
Sunset Yellow FCF (Sunset yellow) 是一种橙色偶氮染料,吸光度具有pH 依赖性。Sunset Yellow FCF 可在食品,化妆品和药品中使用,在许多食品中用作着色剂食品添加剂,它们可能具有细胞毒性和遗传毒性,因此在使用这些材料作为食品添加剂时必须小心。 | |||
TN1970 |
N-trans-p-coumaroyloctopamine
N-p-Coumaroyloctopamine,N-对香豆酰真蛸胺,p-coumaroylnoradrenaline |
Others | Others |
N-trans-p-coumaroyloctopamine (p-coumaroylnoradrenaline) 来源于马铃薯的块茎组织。 | |||
T3829 |
Ginsenoside F3
人参皂苷F3 |
Others; IFNAR; Interleukin | Immunology/Inflammation; Others |
Ginsenoside F3 是一种皂苷,提取自Panax ginseng 叶片。它能够调节1 型 (IL-2, IFN-γ) 及 2 型细胞因子(IL-4 and IL-10) 的产生和表达,有免疫增强的作用。 | |||
T64744 |
Ovalbumins
|
Endogenous Metabolite | Metabolism |
Ovalbumins 是蛋清中的主要蛋白质。Ovalbumins 具有多种生物活性,如降压、抗菌、抗癌、抗氧化和免疫调节活性。Ovalbumins 是雌激素或孕酮处理的输卵管中合成的丰富的蛋白质。Ovalbumins 通常用作研究激素控制该组织中基因表达的标志物。 | |||
T2814 |
Cryptotanshinone
隐丹参酮,Cryptotanshinon,Tanshinone c,隐丹参醌 |
STAT; Autophagy | Autophagy; JAK/STAT signaling; Stem Cells |
Cryptotanshinone (Cryptotanshinon) 是从丹参的根中提取的一种天然产物,抑制STAT3的IC50为4.6 μM,具有抗肿瘤活性。 | |||
T16016 |
Maytansinol
美登醇,Ansamitocin P-0 |
Apoptosis; Microtubule Associated | Apoptosis; Cytoskeletal Signaling |
Maytansinol (Ansamitocin P-0) 在体外抑制微管组装并导致微管分解。它与辐射联用,用于果蝇和人类癌细胞。 | |||
T11398 |
Ginsenoside Ra3
人参皂苷 RA3,人参皂苷RA3 |
Others | Others |
Ginsenoside Ra3 是分离自人参中,具有抗癌作用。 | |||
T4987 |
NSC 42196
Calcium α-D-heptagluconate hydrate,葡庚糖酸钙水合物,Calcium glucoheptonate |
Others; Endogenous Metabolite | Metabolism; Others |
NSC 42196 (Calcium glucoheptonate) 是内源性代谢产物的一种。 | |||
T3918 |
Ginsenoside Rb3
人参皂苷 Rb3,Gypenoside IV,人参皂苷Rb3 |
NF-κB; COX; NO Synthase | Immunology/Inflammation; Neuroscience; NF-κB |
Ginsenoside Rb3 (Gypenoside IV) 是从三七中提取的一种天然产物。它在 293T 细胞系中抑制 TNFα 诱导的NF-κB 转录活性,IC50为 8.2 μM。它还抑制COX-2和iNOSmRNA 的诱导。 | |||
T3830 |
20(R)-Ginsenoside Rg2
20R-Ginsenoside Rg2,20R-人参皂苷Rg2,20(R)-人参皂苷 Rg2 |
IL Receptor | Immunology/Inflammation |
20(R)-Ginsenoside Rg2 (20R-Ginsenoside Rg2) 是一种人参皂苷。它能够抑制肺癌 NCI-H1650 细胞,具有抗癌作用。 | |||
T2873 |
Ginsenoside Rg2
Chikusetsusaponin I,Panaxoside Rg2,人参皂苷Rg2,Prosapogenin C2,(20S)Ginsenoside Rg2,人参皂苷 Rg2 |
Beta Amyloid; GSK-3; NF-κB | Neuroscience; NF-κB; PI3K/Akt/mTOR signaling; Stem Cells |
Ginsenoside Rg2 (Chikusetsusaponin I) 是一种人参的主要活性成分。它能够降低Aβ1-42积聚,抑制脂多糖介导的VCAM-1和ICAM-1表达的增加。 | |||
T2822 |
Ginsenoside Rb1
Gypenoside Ⅲ,人参皂苷Rb1,人参皂苷 Rb1,Gypenoside III |
ATPase; Mitophagy; IRAK; NF-κB; Autophagy; HSV | Autophagy; Immunology/Inflammation; Membrane transporter/Ion channel; Microbiology/Virology; NF-κB |
Ginsenoside Rb1 (Gypenoside Ⅲ) 是中药人参的成分,可能具有抑制或阻止肿瘤生长的特性。 | |||
T0762 |
Trans-Anethole
茴香烯,(E)-Anethole,4-Propenylanisole |
Others; Endogenous Metabolite | Metabolism; Others |
Trans-Anethole ((E)-Anethole) 是一种从Pimpinella 分离得到的苯丙烯衍生物,是茴香、桃金娘、甘草、樟脑等植物中重要气味的组成部分。它在肿瘤细胞系中,低浓度下有雌激素特性,而在高浓度下具有细胞毒性。 | |||
T2959 |
Ginsenoside Rh2
20(S)-Rh2,20S-Ginsenoside Rh2,人参皂苷Rh2,20(S)-Ginsenoside Rh2,人参皂苷 Rh2 |
Apoptosis; EGFR; Caspase; Endogenous Metabolite | Angiogenesis; Apoptosis; JAK/STAT signaling; Metabolism; Proteases/Proteasome; Tyrosine Kinase/Adaptors |
Ginsenoside Rh2 (20(S)-Ginsenoside Rh2) 诱导caspase-8和caspase-9活化。它以多途径方式诱导癌细胞凋亡。 | |||
T5S1103 |
Isoliensinine
异莲心碱,Isoliensinin |
Apoptosis; Antioxidant | Apoptosis; oxidation-reduction |
Isoliensinine (Isoliensinin) 是从水芙蓉种子胚中提取的一种双苄基异喹啉生物碱,能诱导三阴性乳腺癌细胞凋亡,具有抗氧化、抗炎、抗癌活性。 | |||
T6S1485 |
Ginsenoside Rh4
人参皂苷Rh4 |
Others | Others |
Ginsenoside Rh4 可以安全地用作佐剂,具有低溶血作用或无溶血作用。它具有细胞毒活性,其苷元对癌细胞系具有杀伤作用。 | |||
T21651 |
Lansoprazole sodium
兰索拉唑钠,Lansoprazole (sodium), AG-1749 sodium |
Proton pump; Phospholipase; Antibacterial | Membrane transporter/Ion channel; Metabolism; Microbiology/Virology |
Lansoprazole sodium (Lansoprazole (sodium)) 是一种质子泵抑制剂,是中性鞘磷脂酶的外泌体抑制剂,能抑制胃酸生成。 | |||
TN5028 |
Sinensin
ZINC38908691 |
Others | Others |
Sinensin 是一种来自 Cudrania cochinchinensis 的草本植物中的类黄酮。 | |||
T7883 |
Proanthocyanidins
Procyanidin |
Antibacterial; Antifungal | Microbiology/Virology |
Proanthocyanidins 是一类在高等植物中广泛分布的多酚化合物,用作抗氧化剂和抗癌剂。它可研究慢性静脉功能不全、毛细血管脆弱、晒伤和视网膜病变,有抗炎、抗菌、抗真菌和保护心脏的特性。 | |||
------------------------ 更多 ------------------------ |
Cat. No. | Product Name | Species | Expression System |
---|---|---|---|
TMPH-03487 |
DNA-binding protein H-NS Protein, SerRatia marcescens, Recombinant (His)
hnsA,hns,Histone-like protein HLP-II,DNA-b... |
Serratia marcescens | E. coli |
A DNA-binding protein implicated in transcriptional repression and chromosome organization and compaction. Binds nucleation sites in AT-rich DNA and bridges them, forming higher-order nucleoprotein complexes and condensing the chromosome. As many horizontally transferred genes are AT-rich, it plays a central role in silencing foreign genes. A subset of genes are repressed by H-NS in association with other proteins. DNA-binding protein H-NS Protein, SerRatia marcescens, Recombinant (His) is expre... | |||
TMPH-00616 |
DNA-binding protein H-NS Protein, E. coli, Recombinant (His)
hns,DNA-binding protein H-NS,Protein B1,Pr... |
E. coli | E. coli |
A DNA-binding protein implicated in transcriptional repression (silencing). Also involved in bacterial chromosome organization and compaction. H-NS binds tightly to AT-rich dsDNA and inhibits transcription. Binds upstream and downstream of initiating RNA polymerase, trapping it in a loop and preventing transcription. Binds to hundreds of sites, approximately half its binding sites are in non-coding DNA, which only accounts for about 10% of the genome. Many of these loci were horizontally transfe... | |||
TMPY-01888 |
KRAS Protein,Human, Recombinant (Q61H, His)
KRAS2,C-K-RAS,Kirsten rat sarcoma viral oncogene homolog,K-R... |
Human | E. coli |
KRAS Protein,Human, Recombinant (Q61H, His) is expressed in E. coli expression system with His tag. The predicted molecular weight is 22.5 kDa and the accession number is P01116-2. | |||
TMPY-04116 |
KRAS Protein,Human,Recombinant(G12C & Q61H, His)
NS,CFC2,K-RAS4B,C-K-RAS,KRAS2,K-RAS2B,K-RAS,Kirsten... |
Human | E. coli |
KRAS Protein,Human,Recombinant(G12C & Q61H, His) is expressed in E. coli expression system with His tag. The predicted molecular weight is 23.3 kDa and the accession number is P01116-2. | |||
TMPY-06056 |
KRAS Protein, Human, Recombinant (G12D, His)
KRAS1,K-RAS4B,Kirsten rat sarcoma viral oncogene homolog,RAL... |
Human | E. coli |
KRAS Protein, Human, Recombinant (G12D, His) is expressed in E. coli expression system with His tag. The predicted molecular weight is 22 kDa and the accession number is P01116-2. | |||
TMPY-04113 |
KRAS Protein,Human,Recombinant(G12D & Q61H, His)
Kirsten rat sarcoma viral oncogene homolog,KRAS2,KI-RAS,RASK... |
Human | E. coli |
KRAS Protein,Human,Recombinant(G12D & Q61H, His) is expressed in E. coli expression system with His tag. The predicted molecular weight is 23.3 kDa and the accession number is P01116-2. | |||
TMPY-00323 |
Hepatitis C virus (HCV-1a) NS3 protease/helicase immunodominant region Protein (aa 1356-1459, GST)
NS3 |
HCV | E. coli |
HCV NS3 displays three enzymatic activities: serine protease, NTPase, and RNA helicase. HCV NS3 serine protease, in association with NS4A, is responsible for the cleavages of NS3-NS4A, NS4A-NS4B, NS4B-NS5A, and NS5A-NS5B. HCV NS3 RNA helicase binds to RNA and unwinds dsRNA in the 3' to 5' direction, and likely RNA stable secondary structure in the template strand (By similarity). Cleaves and inhibits the host antiviral protein MAVS. NS3/NS4A complex also prevents phosphorylation of human IRF3, t... | |||
TMPY-02628 |
Neuroserpin Protein, Mouse, Recombinant (His)
PI12,serpin peptidase inhibitor, clade I (neuroserpin), memb... |
Mouse | HEK293 Cells |
Neuroserpin Protein, Mouse, Recombinant (His) is expressed in HEK293 mammalian cells with His tag. The predicted molecular weight is 46 kDa and the accession number is O35684. | |||
TMPY-04870 |
Zika virus (ZIKV) (strain Zika SPH2015) ZIKV-NS1 protein (His)
|
ZIKV | HEK293 Cells |
Zika virus NS1 antigen is one of seven non-structural proteins. NS1 is involved in RNA replication. The possible effects of NS1 on hosts include: localizes to host cell surface and secreted extracellularly, modulates signalling of the innate immune system, has possible damages to platelets and endothelial cells through anti-NS1 antibodies. | |||
TMPY-00052 |
Dengue virus (DENV) (type 2, strain New Guinea C) NS1 Protein (His)
DENV-NS1 |
DENV | HEK293 Cells |
Dengue virus (DENV) (type 2, strain New Guinea C) NS1 Protein (His) is expressed in HEK293 mammalian cells with His tag. The predicted molecular weight is 42.3 kDa and the accession number is AAC59275.1. | |||
TMPY-06345 |
KRAS Protein, Human, Recombinant (His & Avi), Biotinylated
RASK2,K-RAS2A,RALD,C-K-RAS,NS3,Kirsten rat sarcoma ... |
Human | E. coli |
KRAS Protein, Human, Recombinant (His & Avi), Biotinylated is expressed in E. coli expression system with His and Avi tag. The predicted molecular weight is 23.78 kDa and the accession number is P01116-2. | |||
TMPY-06138 |
KRAS Protein, Human, Recombinant (61Q, His)
Kirsten rat sarcoma viral oncogene homolog,K-RAS2B,NS |
Human | E. coli |
KRAS Protein, Human, Recombinant (61Q, His) is expressed in E. coli expression system with His tag. The predicted molecular weight is 21.9 kDa and the accession number is P01116-2. | |||
TMPY-04903 |
Dengue virus (DENV) (type 3, strain Philippines/H87/1956) NS1 Protein (His)
DENV-NS1 |
DENV | HEK293 Cells |
Dengue virus (DENV) (type 3, strain Philippines/H87/1956) NS1 Protein (His) is expressed in HEK293 mammalian cells with His tag. The predicted molecular weight is 42.1 kDa and the accession number is AAA99437.1. | |||
TMPH-01849 |
Human parvovirus B19 (isolate AU) Non-capsid protein NS-1 (His & SUMO)
|
HPV B19 | E. coli |
Human parvovirus B19 (isolate AU) Non-capsid protein NS-1 (His & SUMO) is expressed in E. coli expression system with N-6xHis-SUMO tag. The predicted molecular weight is 44.6 kDa and the accession number is P07298. | |||
TMPU-00001 |
KRAS Protein, Human, Recombinant (G12S, GST)
NS,C-K-RAS,K-RAS2A,KRAS1,K-RAS2B,KRAS2,K-RAS4A,CFC2... |
Human | E. coli |
KRAS Protein, Human, Recombinant (G12S, GST) is expressed in E. coli expression system with GST tag. The accession number is P01116. | |||
TMPY-02219 |
Influenza A H1N1 (A/Puerto Rico/8/34/Mount Sinai) Non-structural/NS1 Protein (His)
NS1 Protein |
H1N1 | E. coli |
The NS1 Influenza protein is created by the internal protein-encoding, linear negative-sense, single-stranded RNA, NS gene segment and which also codes for the nuclear export protein or NEP, formerly referred to as the NS2 protein, which mediates the export of vRNPs. The non-structural (NS1) protein is found in Influenzavirus A, Influenzavirus B, and Influenzavirus C. The non-structural (NS1) protein of the highly pathogenic avian H5N1 viruses circulating in poultry and waterfowl in Southeast As... | |||
TMPK-01405 |
HLA-A*11:01&B2M&KRAS G12V (VVVGAVGVGK) Monomer Protein, Human, MHC (E. coli, His & Avi)
KI-RAS,RASK2,K-Ras 2,MHC,KRAS,KRAS1,NS3,K-RAS2A,K-R... |
Human | E. coli |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01428 |
HLA-A*11:01&B2M&KRAS G12D (VVGADGVGK) Monomer Protein, Human, MHC (His & Avi)
CFC2,K-RAS4B,K-Ras 2,C-K-RAS,RASK2,NS3,RALD,KI-RAS,... |
Human | E. coli |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01443 |
HLA-A*11:01&B2M&KRAS G12V (VVVGAVGVGK) Monomer Protein, Human, MHC (His & Avi), FITC-Labeled
KRAS1,C-K-RAS,K-RAS4B,RALD,K-Ras 2,K-RAS2A,K-RAS2B,KRAS2, |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01450 |
HLA-C*03:04&B2M&KRAS G12D (GADGVGKSAL) Monomer Protein, Human, MHC (His & Avi), Biotinylated
KRAS1,MHC,K-RAS4B,KRAS,CFC2,K-RAS2B,K-Ras 2,C-K-RAS,RASK2,K-... |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01462 |
HLA-A*11:01&B2M&KRAS G12C (VVVGACGVGK) Monomer Protein, Human, MHC (His & Avi), Biotinylated
K-RAS4A,K-RAS2A,CFC2,KRAS1,K-RAS4B,C-K-RAS,KRAS,K-RAS2B,K-Ra... |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01511 |
HLA-A*03:01&B2M&KRAS WT (VVVGAGGVGK) Monomer Protein, Human, MHC (His & Avi), Biotinylated
GTPase Kras,K-RAS4A,KI-RAS,K-RAS4B,C-K-RAS,K-Ras 2,RASK2,K-R... |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. | |||
TMPK-01460 |
HLA-A*11:01&B2M&KRAS G12S (VVVGASGVGK) Monomer Protein, Human, MHC (His & Avi), Biotinylated
MHC,K-RAS2A,KI-RAS,K-RAS4B,RALD,NS3,GTPase Kras,K-R... |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01403 |
HLA-A*11:01&B2M&KRAS G12V (VVGAVGVGK) Monomer Protein, Human, MHC (E. coli, His & Avi)
K-Ras 2,KI-RAS,CFC2,KRAS1,GTPase Kras,KRAS,K-RAS4B,RALD,... |
Human | E. coli |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01427 |
HLA-A*11:01&B2M&KRAS G12D (VVGADGVGK) Monomer Protein, Human, MHC (His & Avi), Biotinylated
C-K-RAS,K-RAS4B,GTPase Kras,K-RAS4A,K-RAS2A,KRAS2,CFC2,RASK2... |
Human | E. coli |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01399 |
HLA-A*11:01&B2M&KRAS WT (VVGAGGVGK) Monomer Protein, Human, MHC (His & Avi), Biotinylated
K-RAS2A,NS3,KRAS2,CFC2,K-RAS4B,GTPase Kras,RALD,MHC... |
Human | E. coli |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. | |||
TMPK-01404 |
HLA-A*11:01&B2M&KRAS G12V (VVVGAVGVGK) Monomer Protein, Human, MHC (E. coli, His & Avi), Biotinylated
NS,KRAS,KRAS1,KRAS2,MHC,RALD,K-RAS4A,K-RAS2A,K-RAS4... |
Human | E. coli |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01479 |
HLA-A*11:01&B2M&KRAS WT (VVVGAGGVGK) Monomer Protein, Human, MHC (His & Avi), Biotinylated
NS3,KRAS1,K-Ras 2,K-RAS2A,K-RAS2B,C-K-RAS,K-RAS4A,C... |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. | |||
TMPK-01461 |
HLA-A*11:01&B2M&KRAS G12S (VVVGASGVGK) Monomer Protein, Human, MHC (His & Avi)
C-K-RAS,KRAS,RASK2,K-Ras 2,K-RAS2A,MHC,CFC2,K-RAS4B,K-RAS2B,... |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01525 |
HLA-A*11:01&B2M&KRAS G12V (VVGAVGVGK) Monomer Protein, Human, MHC (His & Avi), Biotinylated
CFC2,RALD,K-Ras 2,MHC,C-K-RAS,NS3,GTPase Kras,KRAS2... |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01434 |
HLA-A*11:01&B2M&KRAS G12R (VVVGARGVGK) Tetramer Protein, Human, MHC (His & Avi)
RASK2,CFC2,GTPase Kras,KRAS,K-RAS2B,MHC,K-RAS2A,K-RAS4A,KRAS... |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01408 |
HLA-A*02:01&B2M&KRAS G12V (KLVVVGAVGV) Monomer Protein, Human, MHC (His & Avi), Biotinylated
RALD,KRAS1,KRAS2,K-RAS2B,CFC2,NS3,GTPase Kras,MHC,K... |
Human | E. coli |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01401 |
HLA-A*11:01&B2M&KRAS WT (VVVGAGGVGK) Monomer Protein, Human, MHC (E. coli, His & Avi)
MHC,CFC2,K-Ras 2,RALD,K-RAS4A,NS,RASK2,GTPase Kras,... |
Human | E. coli |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. | |||
TMPK-01429 |
HLA-A*11:01&B2M&KRAS G12D (VVVGADGVGK) Monomer Protein, Human, MHC (E. coli, His & Avi), Biotinylated
MHC,K-Ras 2,NS,K-RAS4A,KRAS,NS3,KI-RAS,K-R... |
Human | E. coli |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01451 |
HLA-C 03:04&B2M&KRAS G12D (GADGVGKSAL) Monomer Protein, Human, MHC (His & Avi)
NS3,K-RAS4A,K-Ras 2,NS,KRAS1,RASK2,MHC,KI-... |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01488 |
HLA-A*11:01&B2M&KRAS WT (VVVGAGGVGK) Monomer Protein, Human, MHC (His & Avi)
K-RAS4A,MHC,GTPase Kras,K-Ras 2,KRAS2,K-RAS2B,CFC2,RASK2,RAL... |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. | |||
TMPK-01529 |
HLA-A*11:01&B2M&KRAS G12D (VVVGADGVGK) Monomer Protein, Human, MHC (His & Avi)
K-RAS4A,KRAS1,MHC,K-RAS2B,CFC2,GTPase Kras,K-RAS4B,KRAS2, |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01458 |
HLA-A*11:01&B2M&KRAS G12A (VVVGAAGVGK) Monomer Protein, Human, MHC (His & Avi)
K-Ras 2,GTPase Kras,KRAS2,MHC,K-RAS4A,CFC2,K-RAS2A,KRAS1,RAS... |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01463 |
HLA-A*11:01&B2M&KRAS G12C (VVVGACGVGK) Monomer Protein, Human, MHC (His & Avi)
C-K-RAS,KI-RAS,KRAS1,K-RAS4A,KRAS2,CFC2,MHC,NS3,K-R... |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01518 |
HLA-A*11:01&B2M&KRAS G12V (VVVGAVGVGK) Tetramer Protein, Human, MHC (His & Avi)
MHC,NS,KRAS1,K-RAS2A,GTPase Kras,KRAS,RALD,KRAS2,RA... |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01527 |
HLA-A*03:01&B2M&KRAS G12V (VVVGAVGVGK) Monomer Protein, Human, MHC (His & Avi)
NS,RALD,C-K-RAS,RASK2,K-RAS2B,KRAS2,KRAS,K-RAS2A,K-... |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01510 |
HLA-A*03:01&B2M&KRAS WT (VVVGAGGVGK) Tetramer Protein, Human, MHC (His & Avi)
NS,NS3,KRAS2,RASK2,MHC,RALD,K-Ras 2,K-RAS4... |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. | |||
TMPK-01433 |
HLA-A*11:01&B2M&KRAS G12C (VVVGACGVGK) Tetramer Protein, Human, MHC (His & Avi)
GTPase Kras,NS3,K-Ras 2,K-RAS2B,RALD,MHC,RASK2,K-RA... |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01402 |
HLA-A*11:01&B2M&KRAS G12V (VVGAVGVGK) Monomer Protein, Human, MHC (E. coli, His & Avi), Biotinylated
KRAS1,NS,CFC2,K-RAS4B,RASK2,K-Ras 2,KI-RAS,GTPase K... |
Human | E. coli |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01430 |
HLA-A*11:01&B2M&KRAS G12D (VVVGADGVGK) Monomer Protein, Human, MHC (E. coli, His & Avi)
K-RAS2A,RALD,NS3,K-Ras 2,KI-RAS,NS,MHC,K-R... |
Human | E. coli |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01440 |
HLA-A*11:01&B2M&KRAS G12V (VVVGAVGVGK) Tetramer Protein, Human, MHC (His & Avi), PE-Labeled
RASK2,KI-RAS,C-K-RAS,KRAS,MHC,NS,K-RAS4A,K-RAS2B,CF... |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01432 |
HLA-A*11:01&B2M&KRAS G12A (VVVGAAGVGK) Tetramer Protein, Human, MHC (His & Avi)
RASK2,K-RAS4A,K-RAS4B,KRAS2,CFC2,MHC,KRAS,KI-RAS,K-RAS2B,C-K... |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01528 |
HLA-A*11:01&B2M&KRAS G12V (VVVGAVGVGK) Monomer Protein, Human, MHC (His & Avi)
KRAS1,MHC,K-RAS2B,K-RAS4B,NS,GTPase Kras,K-Ras 2,KI... |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01456 |
HLA-C*03:04&B2M&KRAS G12D (GADGVGKSAL) Tetramer Protein, Human, MHC (His & Avi)
KRAS2,NS,MHC,C-K-RAS,KRAS1,K-RAS2A,K-RAS2B,KI-RAS,K... |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01512 |
HLA-A*03:01&B2M&KRAS WT (VVVGAGGVGK) Monomer Protein, Human, MHC (His & Avi)
K-Ras 2,NS,NS3,K-RAS2B,CFC2,MHC,KRAS1,GTPa... |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. | |||
------------------------ 更多 ------------------------ |